Results 271 to 280 of about 264,616 (357)

SLAMF7 is critical for phagocytosis of haematopoietic tumour cells via Mac-1 integrin

Nature, 2017
Jun Chen, Ming-Chao Zhong, Huaijian Guo, Dominique Davidson, Sabrin Mishel, Yan Lu, Inmoo Rhee, Luis-Alberto Pérez-Quintero, Shaohua Zhang, M. Cruz-Munoz, Ning Wu, D. Vinh, M. Sinha, V. Calderon, C. Lowell, J. Danska, A. Veillette   +16 more
semanticscholar   +1 more source

The Biochemical Basis of Phagocytosis

, 1960
Anthony J. Sbarra, Manfred L. Karnovsky
openalex   +1 more source

Comparative assessment of macrophage responses and antileishmanial efficacy in dynamic vs. Static culture systems utilizing chitosan-based formulations. [PDF]

PLoS One
Riezk A, O'Keeffe A, Van Bocxlaer K, Yardley V, Croft SL.   +4 more
europepmc   +1 more source

TP53‐Mutated Myeloid Neoplasms: 2024 Update on Diagnosis, Risk‐Stratification, and Management

American Journal of Hematology, EarlyView.
ABSTRACT Alterations in the tumor suppressor gene TP53 are common in human cancers and are associated with an aggressive nature. Approximately 8%–12% of myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML) harbor TP53 mutations (TP53mut) and present immense challenges due to inherent chemoresistance and poor outcomes.
Mithun Vinod Shah, Daniel A. Arber, Devendra K. Hiwase   +2 more
wiley   +1 more source

Healthy and premature aging of monocytes and macrophages. [PDF]

Front Immunol
Basu S, Ulbricht Y, Rossol M.
europepmc   +1 more source

Targeted Therapies in Myelofibrosis: Present Landscape, Ongoing Studies, and Future Perspectives

American Journal of Hematology, EarlyView.
ABSTRACT Myelofibrosis (MF) is a myeloproliferative neoplasm that is accompanied by driver JAK2, CALR, or MPL mutations in more than 90% of cases, leading to constitutive activation of the JAK–STAT pathway. MF is a multifaceted disease characterized by trilineage myeloid proliferation with prominent megakaryocyte atypia and bone marrow fibrosis, as ...
Giuseppe G. Loscocco, Paola Guglielmelli
wiley   +1 more source

Belantamab Mafodotin Plus Proteasome Inhibition Efficacy Versus Comparators in Early Relapsed Myeloma: A Systematic Review and Network Meta‐Analysis

American Journal of Hematology, EarlyView.
ABSTRACT In the Phase 3 DREAMM‐7 study of patients with relapsed/refractory multiple myeloma (RRMM) who received ≥ 1 prior therapy, belantamab mafodotin plus bortezomib and dexamethasone (BVd) demonstrated a progression‐free survival (PFS) benefit versus daratumumab plus bortezomib and dexamethasone (DVd).
Joshua Richter, Ajay Nooka, Paula Rodríguez‐Otero, Fredrik Schjesvold, Eirini Katodritou, Emily Combe, Marianne Scott, Leanne Cooper, Indeg Sly, Nick Ballew, Jacopo Bitetti, Natalie Boytsov, Molly Purser, Simon McNamara   +13 more
wiley   +1 more source

Targeting myeloid cells for hematological malignancies: the present and future. [PDF]

Biomark Res
Guan Z, Zhang Z, Wang K, Qiao S, Ma T, Wu L.   +5 more
europepmc   +1 more source

Differential Immune Cell Infiltration in Eosinophilic and Non‐Eosinophilic CRS: Correlations With Clinical, Endoscopic, and Radiological Findings

International Forum of Allergy &Rhinology, EarlyView.
ABSTRACT Background The pathogenesis of inflammation in eosinophilic chronic rhinosinusitis (ECRS) and non‐eosinophilic chronic rhinosinusitis (NECRS) remains poorly understood. This study aimed to assess immune cell infiltration within the sinonasal microenvironment in these conditions.
Katarzyna Czerwaty, Katarzyna Piszczatowska, Mirosław J. Szczepański, Natalia Jermakow, Nils Ludwig, Karolina Dżaman   +5 more
wiley   +1 more source

Expression of SIRPα-Fc by oncolytic virus enhances antitumor efficacy through tumor microenvironment reprogramming. [PDF]

Front Immunol
Yang Q, Shu Y, Chen Y, Qi Z, Hu S, Zhang Y, Qin Y, Xu X, Hu J, Huang A, Cheng P.   +10 more
europepmc   +1 more source